

College of

Institute for Pharmaceutics

Outcomes and Policy

harmacv

Abuse-Deterrent Formulation Opioid Prescribing in California, Florida, and Kentucky

John R. Brown^{1,2}, GYeon Oh^{3,4}, Patricia R. Freeman^{1,2}, Chris Delcher^{1,2}, Yanning Wang⁵, Svetla Slavova^{4,6}

¹University of Kentucky (UK) Department of Pharmacy Practice and Science; ²Institute for Pharmaceutical Outcomes and Policy; ³UK Department of Epidemiology; ⁴Kentucky Injury Prevention and Research Center;



RESULTS

⁵University of Florida Department of Health Outcomes and Biomedical Informatics; ⁵UK Department of Biostatistics The authors acknowledge the Kentucky All Schedule Prescription Electronic Reporting System (KASPER) Staff with the KY Cabinet for Health and Family Services for support of this project.

BACKGROUND

- Abuse-deterrent formulation (ADF) opioids are designed to deter abuse by known or expected routes (e.g. crushing to snort or dissolving to inject)
- The U.S. Food and Drug Administration (FDA) encourages ADF opioid development as a means to address the opioid epidemic There are five brand name ADF opioid products commercially available in the U.S.
- Use of ADF opioids within clinical practice is not well understood and may vary based upon patient- and policy-level factors

STUDY OBJECTIVE

To characterize prescribing of ADF opioids in 3 states with diverse opioid prescribing patterns

METHODS

Data Sources: Prescription Drug Monitoring Programs from California, Florida, and Kentucky

Analyses of ADF prescribing:

- Included patients ≥ 18 years with at least one prescription record for an ADF opioid in calendar year 2018
- Prescribing rates were calculated according to age, gender, and rurality and were standardized per 1,000 adults in the population and per 1,000 users of opioids, with comparisons expressed as rate ratios
- Rurality was classified at the county-level based on adjacency to a metro area
- ADF uptake was expressed as number of prescriptions and number of distinct ADF users and was evaluated by payer source
- Choropleth maps were used to visualize county-level ADF prescribing rates per 1,000 users of opioids

DISCLOSURE

This study is supported by funding from the U.S. Food and Drug Administration and the Bureau of Justice Assistance.

State				Users of ADF Op	bioids, 2018						
	Califo				Table 1. Patient Demographics of Adult Users of ADF Opioids, 2018						
		California		Florida		Kentucky					
	(per 1,000 adults)	Rate Ratio (95% CI)	ADF Use Rate (per 1,000 adults)	Rate Ratio (95% CI)	ADF Use Rate (per 1,000 adults)	Rate Ratio (95% CI)					
Overall	1.60		2.95		2.09						
Age (years)											
18-24	0.11	0.14 (0.13-0.16)	0.12	0.07 (0.06-0.08)	0.07	0.06 (0.04-0.09)					
25-34	0.30	0.39 (0.37-0.42)	0.56	0.31 (0.29-0.33)	0.26	0.22 (0.19-0.27)					
35-44	0.77	REF	1.82	REF	1.15	REF					
45-54	1.59	2.08 (2.00-2.16)	3.55	1.95 (1.88-2.02)	2.71	2.35 (2.15-2.58)					
55-64	3.12	4.07 (3.93-4.21)	5.87	3.22 (3.12-3.33)	4.25	3.69 (3.38-4.02)					
65-74	3.83	5.00 (4.83-5.18)	4.71	2.58 (2.50-2.67)	3.79	3.29 (3.00-3.61)					
<u>></u> 75	2.98	3.89 (3.74-4.04)	3.08	1.69 (1.62-1.75)	2.23	1.93 (1.73-2.16)					
Gender											
Male	1.50	REF	2.90	REF	2.13	REF					
Female	1.70	1.13 (1.12-1.16)	2.99	1.03 (1.01-1.05)	2.05	0.96 (0.92-1.00)					
Rurality											
Metro	1.52	REF	2.92	REF	1.89	REF					
NMAM	3.17	2.09 (1.99-2.20)	3.73	1.28 (1.22-1.34)	2.05	1.08 (1.02-1.16)					
NMNAM	2.43	1.60 (1.47-1.75)	3.45	1.18 (0.79-1.76)	2.28	1.21 (1.14-1.27)					

Total adult population per state: 30,567,090 (CA); 17,070,244 (FL); 3,459,973 (KY)





Figure 1. County-level ADF Use Rates per 1,000 Adult Users of Opioids, 2018



PRINCIPAL FINDINGS

- Rates of ADF prescribing varied by age and were greatest among patients ages 55 to 74 years
- ADF prescribing rates appeared to vary by rurality both within and among states and were lowest in metro areas with higher rates clustered in some areas
- OxyContin[®] accounted for a majority of ADF prescriptions in all three states
- Most ADF prescriptions were paid via insurance; private pay accounted for less than 16% of total claims
- Further research is necessary to understand what factors may impact differences in ADF prescribing